JP2008518905A - スルホニルベンゾイミダゾール誘導体 - Google Patents

スルホニルベンゾイミダゾール誘導体 Download PDF

Info

Publication number
JP2008518905A
JP2008518905A JP2007538543A JP2007538543A JP2008518905A JP 2008518905 A JP2008518905 A JP 2008518905A JP 2007538543 A JP2007538543 A JP 2007538543A JP 2007538543 A JP2007538543 A JP 2007538543A JP 2008518905 A JP2008518905 A JP 2008518905A
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
dimethylpropyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007538543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518905A5 (enExample
Inventor
香奈 紺井
都 松水
晃子 島
Original Assignee
ファイザー株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー株式会社 filed Critical ファイザー株式会社
Publication of JP2008518905A publication Critical patent/JP2008518905A/ja
Publication of JP2008518905A5 publication Critical patent/JP2008518905A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007538543A 2004-11-02 2005-10-19 スルホニルベンゾイミダゾール誘導体 Pending JP2008518905A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62457804P 2004-11-02 2004-11-02
US69635805P 2005-06-30 2005-06-30
PCT/IB2005/003325 WO2006048754A1 (en) 2004-11-02 2005-10-19 Sulfonyl benzimidazole derivatives

Publications (2)

Publication Number Publication Date
JP2008518905A true JP2008518905A (ja) 2008-06-05
JP2008518905A5 JP2008518905A5 (enExample) 2008-11-27

Family

ID=35915103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538543A Pending JP2008518905A (ja) 2004-11-02 2005-10-19 スルホニルベンゾイミダゾール誘導体

Country Status (18)

Country Link
US (1) US7598393B2 (enExample)
EP (1) EP1809607B1 (enExample)
JP (1) JP2008518905A (enExample)
AR (1) AR053774A1 (enExample)
AT (1) ATE417830T1 (enExample)
BR (1) BRPI0517925A (enExample)
CA (1) CA2586179C (enExample)
DE (1) DE602005011844D1 (enExample)
DO (1) DOP2005000221A (enExample)
ES (1) ES2318556T3 (enExample)
GT (1) GT200500309A (enExample)
MX (1) MX2007005290A (enExample)
NL (1) NL1030324C2 (enExample)
PA (1) PA8651501A1 (enExample)
PE (1) PE20060937A1 (enExample)
TW (1) TW200621724A (enExample)
UY (1) UY29184A1 (enExample)
WO (1) WO2006048754A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084767A1 (en) * 2009-01-22 2010-07-29 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
JP2011506549A (ja) * 2007-12-17 2011-03-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フルオロアルキル置換ベンズイミダゾールカンナビノイドアゴニスト

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
EA016286B1 (ru) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
EP1960389B1 (en) * 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US7700618B2 (en) 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
CA2654246A1 (en) * 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US8541476B2 (en) * 2007-09-14 2013-09-24 The Trustees Of The University Of Pennsylvania Compounds for treatment of malignant tumors
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
RU2636614C2 (ru) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
MX2012005248A (es) 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
CN105566182B (zh) * 2016-02-24 2018-02-13 苏州天马精细化学品股份有限公司 一种2‑氨基‑4‑（乙磺酰基）苯酚的合成方法
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
US10569189B1 (en) * 2019-05-17 2020-02-25 NextLeaf Solutions Ltd. Method for acetylation of cannabinoids
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1481049A (fr) * 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
US4177057A (en) * 1977-10-25 1979-12-04 United States Borax & Chemical Corporation Herbicidal benzimidazoles
WO1999040072A1 (de) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg 5-gliedrige benzokondensierte heterocyclen als antithrombotika
JP2000159749A (ja) * 1995-12-28 2000-06-13 Fujisawa Pharmaceut Co Ltd ベンズイミダゾ―ル誘導体
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds
WO2004035548A1 (en) * 2002-10-16 2004-04-29 Astrazeneca Ab Novel compounds
WO2005030762A1 (en) * 2003-09-26 2005-04-07 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198633A (en) 1967-11-24 1970-07-15 Ilford Ltd Phenyl-Sulphonated Benzimidazoles
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE19507913C2 (de) * 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
FR2751649B1 (fr) * 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
KR20030088508A (ko) * 2001-04-20 2003-11-19 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP4953455B2 (ja) * 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規なベンゾイミダゾール誘導体
CA2582356A1 (en) * 2004-09-30 2006-04-13 Janssen Pharmaceutica N.V. Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1481049A (fr) * 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
US4177057A (en) * 1977-10-25 1979-12-04 United States Borax & Chemical Corporation Herbicidal benzimidazoles
JP2000159749A (ja) * 1995-12-28 2000-06-13 Fujisawa Pharmaceut Co Ltd ベンズイミダゾ―ル誘導体
WO1999040072A1 (de) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg 5-gliedrige benzokondensierte heterocyclen als antithrombotika
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds
WO2004035548A1 (en) * 2002-10-16 2004-04-29 Astrazeneca Ab Novel compounds
WO2005030762A1 (en) * 2003-09-26 2005-04-07 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506549A (ja) * 2007-12-17 2011-03-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フルオロアルキル置換ベンズイミダゾールカンナビノイドアゴニスト
WO2010084767A1 (en) * 2009-01-22 2010-07-29 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
JP2012515712A (ja) * 2009-01-22 2012-07-12 ラクオリア創薬株式会社 Ｃｂ２受容体作動活性を有するｎ−置換飽和ヘテロ環スルホン化合物
US8653063B2 (en) 2009-01-22 2014-02-18 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity

Also Published As

Publication number Publication date
ES2318556T3 (es) 2009-05-01
WO2006048754A1 (en) 2006-05-11
CA2586179A1 (en) 2006-05-11
CA2586179C (en) 2011-02-08
UY29184A1 (es) 2006-06-30
DE602005011844D1 (de) 2009-01-29
US7598393B2 (en) 2009-10-06
NL1030324C2 (nl) 2006-11-27
GT200500309A (es) 2006-09-11
AR053774A1 (es) 2007-05-23
PE20060937A1 (es) 2006-10-19
ATE417830T1 (de) 2009-01-15
TW200621724A (en) 2006-07-01
US20060094750A1 (en) 2006-05-04
DOP2005000221A (es) 2006-05-15
EP1809607A1 (en) 2007-07-25
PA8651501A1 (es) 2006-06-02
NL1030324A1 (nl) 2006-05-03
BRPI0517925A (pt) 2008-10-21
EP1809607B1 (en) 2008-12-17
MX2007005290A (es) 2007-07-09

Similar Documents

Publication Publication Date Title
US7700618B2 (en) Sulfonyl benzimidazole derivatives
US7598393B2 (en) Sulfonyl benzimidazole derivatives
JP5816883B2 (ja) Ｃｂ２受容体作動活性を有するｎ−置換飽和ヘテロ環スルホン化合物
JP4481344B2 (ja) クロマン置換ベンゾイミダゾール誘導体及び酸ポンプ阻害剤としてのそれらの使用
JP2010503654A (ja) ベンゾイミダゾロン誘導体
JP5140080B2 (ja) 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
JP2007533613A (ja) ５−ｈｔ４受容体作動活性を有するベンズイミダゾロン化合物
JP2009507900A (ja) 高血圧の処置のためのレニン阻害剤としての５−アミノ−４−ヒドロキシ−７−（イミダゾ［１，２−ａ］ピリジン−６−イルメチル）−８−メチル−ノナミド誘導体および関連化合物
JP2008543824A (ja) アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体
US8138177B2 (en) Benzimidazolone derivatives as CB2 receptor ligands
ES2351063T3 (es) Derivados de sulfonilbenzimidazol.
JPWO2007007890A1 (ja) Ｎ−ジヒドロキシアルキル置換２−オキソイミダゾール誘導体
HK1164294A (en) N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081009

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081009

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120604